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samples, and inter- and intra-observer error. For this reason, sev-
eral simple non-invasive clinical scoring systems have been pro-
posed to diagnose advanced ﬁbrosis in NAFLD [1].
We read with great interest the article by Rufﬁllo et al. that
compares the NAFLD ﬁbrosis score and BARD score in predicting
ﬁbrosis in NAFLD [2]. In their retrospective analysis, they con-
cluded that both scoring systems were similar in NAFLD. The
results are interesting and likely to contribute to our understand-
ing of this issue; however, we have some concerns about the data
presented by the authors.
Firstly, as mentioned in the text, the presence of impaired
fasting glucose (IFG) or diabetes mellitus (DM) is a component
of the NAFLD ﬁbrosis score. Although it was stated in the article
that some of the patients were diabetic at baseline, there is no
information regarding the glucose tolerance status of the other
subjects. It is well known that NAFLD is strongly associated with
obesity, hypertension, dyslipidemia and also glucose tolerance
abnormalities [3,4]. In addition, all these metabolic problems
are risk factors for DM and also prediabetes, namely IFG and
impaired glucose tolerance (IGT). In light of these data, we think
that some of the study participants may still have overt glucose
dysregulation or DM without implementation of the glucose tol-
erance test. Secondly, no information about the medications was
given in the text. Yet, we know that liver enzymes are easily
affected by medications started for the metabolic problems men-
tioned above [5,6]. This issue is important because AST/ALT ratio
is another variable in the NAFLD ﬁbrosis score.
We conclude that the presence of major confounders raises
some questions about the data presented, and as such some of
the resulting interpretations should be taken with caution. In
such a case, statistical correlations may also be misleading. It
would be appreciated if the authors could present some more
data adjusted for the topics mentioned above. This could provide
the readers of the journal clearer information in the prediction of
ﬁbrosis by NAFLD ﬁbrosis score in this clinically relevant
condition.
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JOURNAL OF HEPATOLOGYReply to: "Non-invasive prediction of ﬁbrosis in
nonalcoholic fatty liver disease"To the Editor:
We would like to address the concerns presented by Dr. Dogru
et al. in their letter to the Editor. The ﬁrst issue commented on
pertains to one of the six variables included in the formula of
the NAFLD ﬁbrosis score: impaired fasting glucose/diabetes.
For that variable, we took the same deﬁnition from the original
paper by Angulo et al. [1]. Diabetes was deﬁned as a fasting
glucose levelP126 mg/dl or a patient who was already under
treatment with anti-diabetic drugs; and impaired fasting glu-
cose, as a fasting glucose levelP110 mg/dl. We did not perform
any glucose tolerance test in our patients. As stated in our
paper [3], we just retrospectively analyzed data of consecutive
patients with biopsy proven NAFLD that had been prospectively
collected. One advantage of both, the NAFLD ﬁbrosis score and
the BARD score [2], is that they include 6 and 3, respectively,
easily available variables. Being a group that is especially inter-Journal of Hepatology 20ested in research on NAFLD, we had all of these variables avail-
able in our database. In fact, at present if we wanted to repeat
the analysis of comparison between both scoring systems, data
on 182 biopsy proven NAFLD patients would be available
(instead of 138 in our published paper).
The second concern raises the point about the lack of
information on medications that patients could be receiving.
We agree that some drugs may inﬂuence the serum levels
of aspartate aminotransferase (AST) and alanine aminotrans-
ferase (ALT) and we do not have the complete information
about medications taken by our patients. Some of them were
receiving antihypertensive drugs such as enalapril, or antihy-
perlipidemic drugs such as statins. However, the pattern of
liver enzymes in our NAFLD patients conformed to those
commonly found; with a mild to moderate elevation and an
ALT predominance. Median ALT was 69 IU/L, interquartile11 vol. 55 j 497–501 499
range 50–96.5 IU/L and, in only 4 out of 138 patients (2.9%),
levels above 200 IU/L (that is, ﬁve times above upper limit
of normal) were found (maximal value, 294). AST/ALT ratios
in these 4 patients were 0.61, 0.52, 0.78 and 0.55, similar
to the whole group of patients. Thus, we might suggest that
most of the patients were not showing a drug-induced liver
injury able to modify AST or ALT levels. The AST/ALT ratio
is a very important variable, strongly associated with the
presence of advanced ﬁbrosis in the univariate analysis (with
higher odds ratio than other variables) and therefore, is
included in both scoring systems, the NAFLD ﬁbrosis score
and the BARD score. Furthermore, in the BARD score, an
AST/ALT ratioP0.8 sums 2 points while the other two vari-
ables, presence of diabetes or body mass indexP28, sum only
1 point. However, the information on the list of medications
taken by the patients is also lacking in the two original stud-
ies [1,2].
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Gender disparity and MELD in liver transplantation
To the Editor:
We read with great interest the paper by Myers et al. [1], recently
published in Journal of Hepatology, regarding the disparities
between males and females in the MELD-based allocation system
for liver transplantation. The authors found that women are dis-
advantaged under MELD, which may be attributable to the use of
serum creatinine (Cr) in MELD score equation [1]. This conﬁrms
our previously published work indicating a systematic bias
against women [2]. It is known that Cr is an inaccurate marker
of renal function, since its concentration is inﬂuenced by several
factors unrelated to renal function, such as total muscle mass,
leading to discrepancies in Cr concentration between individuals
with the same renal function [same glomerular ﬁltration rate
(GFR)] but of different age, race and sex [3].
We showed that Cr and GFR in females were lower than
males, and female gender might negatively inﬂuence the chances
of receiving a liver transplant with respect to men [2]. Correcting
Cr by equalising the GFR between men and women, resulted in an
increase in MELD score by up to 3 points in female LT candidates
[2]. Following this, Moylan et al. evaluated the UNOS database [4]
and showed that women were more likely to die on the waiting
list in the post-MELD era, compared to the pre-MELD one,
although women were listed with lower median MELD scores,
compared to men (14 vs. 15, p <0.001) [4]. In the UNOS database,
Myers et al. [1] found the same discrepancies, as we did [2]:
women, compared with men, had lower Cr (0.9 vs. 1.0 mg/dl,
and MELD 16.5 vs. 17.2, both p <0.001), but worse renal function
(estimated GFR: 72 vs. 83 mL/min, p <0.001); however they were
less likely to undergo liver transplantation (LT), and had greater
3-month mortality. Interestingly, Myers et al. [1] also found that
patients with cirrhosis with a black ethnicity had a lower mortal-
ity, compared to white ethnicity. We believe that this likely to be
related to Cr: black patients as a group have a higher Cr (more
muscle mass), compared to white, for the same renal function,
and, thus, MELD score may overestimate the severity of their liver
disease. Indeed, MDRD calculations of GFR commonly have a cor-
rection factor for black race.
However Myers et al. did not ﬁnd that using a calculated GFR
(eGFR based on MDRD formula) helped to discriminate a different
prognosis for men vs. women [1]. However, the evaluation with
eGFR (MDRD formula), and not with ‘‘true’’ GFR using a gold stan-
dard method, could explain the discrepant results regarding the
comparison presented of MELD-(Sodium)-eGFR and MELD-
(Sodium) as the authors themselves suggested [1]. In contrast,
Lim et al. [5] (using 125I-iothalamate for true GFR) found that
‘‘true’’ GFR was superior to Cr in assessing mortality risk on the
waiting list and its incorporation in the MELD score (in the place
of Cr), led to a signiﬁcant improvement of discriminative ability
of MELD. Unfortunately, Lim et al. [5] did not evaluate the prog-
nostic impact of MELD-Cr and MELD-GFR scores in men and
women candidates separately.
Secondly, it is possible that the higher mortality of women
placed on waiting lists for liver transplantation [1,4], compared
to men, could be related to the presence of signiﬁcant differences
for matching of donor organ size to either recipient men or
women, and thus, longer waiting times for women compared to
men. Unfortunately, Myers et al. [1] did not evaluate this param-
eter. However, Lai et al. [6] recently suggested that height con-
tributes to the gender disparity, possibly reﬂecting differences
in transplantation rates for shorter individuals. The authors
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